viewAnteris Technologies Ltd

Admedus progressing towards securing $18 million investment for immunotherapies division

The company's shares are trading about 4% higher intra-day, at 24 cents.

funding representation
A new company to be established with Admedus retaining a 29.1% shareholding

Admedus Ltd (ASX:AHZ) has made progress towards securing a long-term funding arrangement for Admedus Vaccines Pty Ltd with Hong Kong investor Star Bright Holding Ltd by executing a Memorandum of Understanding (MOU).

In April, Admedus Vaccines entered into a Letter of Intent with Star Bright who paid a non-refundable break-fee of $500,000 to finalise the terms of an investment of $18 million.

READ: Admedus enters into letter of intent to arrange alternative funding for immunotherapies division

The $18 million investment will be retained in the immunotherapies business to support ongoing research and development, as well as operational activities.

Admedus chairman Wayne Paterson said: “Today’s signing of the MOU is an important step in this process and we look forward to continuing negotiations with Star Bright who share our enthusiasm for the work of Professor Frazer and the Admedus Vaccines team.

“We are committed to securing a final agreement that will enable Admedus Vaccines to continue their ground-breaking research into vaccines and alternative treatment options for a variety of cancers and chronic diseases.”

READ: Admedus raises $2.76 million from share purchase plan

Key terms of the MOU with Star Bright include:

• A new company to be established with Admedus retaining a 29.1% shareholding in the new entity.

• Wayne Paterson to serve on the new company board as chairman for a minimum of five years.

• Professor Ian Frazer to provide principal researcher and chief scientific officer services to the company.

• Initial investment to focus on HSV-2 and HPV head and neck cancer vaccines in the first two years.

• An application for listing of the new company on the Hong Kong Stock Exchange to be planned, subject to regulatory requirements.

Quick facts: Anteris Technologies Ltd

Price: 4 AUD

Market: ASX
Market Cap: $23.64 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read